"Semaglutide's Heart-Healthy Benefits Boost Novo Nordisk and Eli Lilly's Outlook"
TL;DR Summary
Data released by Novo Nordisk confirms that their weight loss drug Wegovy can reduce the risk of strokes and heart attacks, but concerns over the cost of the medicine remain.
Topics:top-news#biotech-and-pharma#cost#novo-nordisk#strokes-and-heart-attacks#wegovy#weight-loss-drugs
- The Outlook for Weight-Loss Drugs Just Got 'Turbocharged.' It's Good for Eli Lilly, Novo Nordisk. - Barrons Barron's
- Weight loss drug may improve heart health, new research finds NBC News
- Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss Yahoo Finance
- Wegovy cuts risk of serious heart problems by 20%: landmark study New York Post
- Semaglutide reduces risk of major cardiovascular events by 20%, finds study The BMJ
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
0 min
vs 1 min read
Condensed
44%
54 → 30 words
Want the full story? Read the original article
Read on Barron's